Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz To Set Up China Headquarters And R&D Center In Chongqing

This article was originally published in PharmAsia News

Executive Summary

Sandoz Pharmaceutical, a subsidiary of Novartis, will set up its China headquarters and R&D center in Chongqing. The constant improvement of the city's investment environment helped convince the firm of its decision. At the same time, Sandoz is seeking to acquire Chongqing Lummy Pharmaceutical for its R&D and innovation capability. After establishing itself, Sandoz China will grow by acquisition and expanding its production capacity in the next five years. It aims to be among the local top-three spots in the sector, with revenue hitting RMB 10 billion ($1.47 billion). (Click here for more - Chinese Language)

You may also be interested in...

RFID Tags Found To Improve Drug Supply Chain Tracking In Recent DSCSA Pilot

A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.

Emergency Clinical Trial Guidance Offers A Peak At The Future Of Virtual Trials: Expert

The current pandemic has accelerated the US FDA’s perspective on conducting remote clinical trials. The agency has published an emergency guidance to allow sponsors to continue their work, which a former FDA official says is an indication of where the agency is headed post-COVID-19.

Umbrella EUA Authorizes Surgical Masks As COVID-19 PPE

Facing ongoing shortages, the US FDA is allowing most surgical masks to be used as personal protective equipment under a new emergency use authorization.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts